Read this news article today: dailymail.co.uk/health/arti...
I try to not get overly excited about these kind of stories, but this potentially looks very promising
Read this news article today: dailymail.co.uk/health/arti...
I try to not get overly excited about these kind of stories, but this potentially looks very promising
This recent AlzForum article provides a good overview/discussion of this NLY01 research (IMHO).
"NLY01 is on a fast track to human testing … with the goal of a Phase 2 in Parkinson’s disease in 2019."
Thank you for sharing this encouraging news, I pray that the clinical trials are successful.
Thank you for posting.
It's here, too. There's a lot of things in the pipeline, but I think the pipeline is 5 years long - at best.
nature.com/articles/s41591-...
Indeed. "The chance for a new [preclinical] drug to actually make it to market is thus only 1 in 5,000" and it takes 12 years typically.
medicinenet.com/script/main...
Yes, I have also read about this taking many years for a new drug to make it to market. But in this case, I thought I had read somewhere where this new drug is using existing drugs that are currently approved in already on the market. So that if the trial results are positive, it could potentially reach the market in much shorter time than is usually the case
Nope. New drug.
Yep, you’re right. I had mixed this up with another article I read recently: medicalnewstoday.com/articl...
Sorry for the confusion.
A Phase 2 trial of another GLP-1 receptor agonist (liraglutide) is currently recruiting PwPs (Cedars-Sinai Medical Center, Los Angeles).
Safety and Efficacy of Liraglutide in Parkinson's Disease: